Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diaphragmatic ultrasound assessment of sugammadex reversal of rocuronium after liver surgery by Child-Pugh class
ChiCTR2000040013Phase 4Not yet recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Jan 2021
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Sugammadex in hepatocellular carcinoma (HCC), hepatic failure and neuromuscular block (NMB) (3 arms), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoints: Postoperative residual incidence of muscle relaxation and Baseline recovery rate of diaphragm. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
Sugammadex
03
Conditions
hepatocellular carcinoma (HCC)hepatic failureneuromuscular block (NMB)
Beyond the preview
Go deeper on ChiCTR2000040013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040013.